Comprehensive Variant Screening of the UGT Gene Family

다국어 초록 (Multilingual Abstract)

Purpose: UGT1A1, UGT2B7, and UGT2B15 are well-known pharmacogenes that belong to the uridine diphosphate glucuronyltransferase gene family. For personalized drug treatment, it is important to study differences in the frequency of core markers across various ethnic groups. Accordingly, we screened single nucleotide polymorphisms (SNPs) of these three genes and analyzed differences in their frequency among five ethnic groups, as well as attempted to predict the function of novel SNPs. Materials and Methods: We directly sequenced 288 subjects consisting of 96 Korean, 48 Japanese, 48 Han Chinese, 48 African American, and 48 European American subjects. Subsequently, we analyzed genetic variability, linkage disequilibrium (LD) structures and ethnic differences for each gene. We also conducted in silico analysis to predict the function of novel SNPs. Results: A total of 87 SNPs were detected, with seven pharmacogenetic core SNPs and 31 novel SNPs. We observed that the frequencies of UGT1A1 *6 (rs4148323), UGT1A1 *60 (rs4124874), UGT1A1 *93 (rs10929302), UGT2B7 *2 (rs7439366), a part of UGT2B7 *3 (rs12233719), and UGT2B15 *2 (rs1902023) were different between Asian and other ethnic groups. Additional in silico analysis results showed that two novel promoter SNPs of UGT1A1 -690G>A and -689A>C were found to potentially change transcription factor binding sites. Moreover, 673G>A (UGT2B7), 2552T>C, and 23269C>T (both SNPs from UGT2B15) changed amino acid properties, which could cause structural deformation. Conclusion: Findings from the present study would be valuable for further studies on pharmacogenetic studies of personalized medicine and drug response.

참고문헌 (Reference)

1 Chen H, "Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy" 37 : 1841-1847, 2009

2 Chen G, "UGT1A1 is a major locus influencing bilirubin levels in African Americans" 20 : 463-468, 2012

3 King CD, "UDP-glucuronosyltransferases" 1 : 143-161, 2000

4 Court MH, "UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver" 310 : 656-665, 2004

5 Yuan P, "Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer" 110 : 2682-2690, 2007

6 Bosma PJ, "The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome" 333 : 1171-1175, 1995

7 Barre L, "Substrate specificity of the human UDP-glucuronosyltransferase UGT2B4 and UGT2B7. Identification of a critical aromatic amino acid residue at position 33" 274 : 1256-1264, 2007

8 Court MH, "Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9" 30 : 1257-1265, 2002

9 Green MD, "Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates" 22 : 799-805, 1994

10 Saeki M, "Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population" 32 : 1048-1054, 2004

11 Gregory PA, "Regulation of UDP glucuronosyltransferases in the gastrointestinal tract" 199 : 354-363, 2004

12 Thiagalingam A, "RREB-1, a novel zinc finger protein, is involved in the differentiation response to Ras in human medullary thyroid carcinomas" 16 : 5335-5345, 1996

13 Bajro MH, "Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer" 205 : 163-167, 2012

14 Mendel D, "Probing protein stability with unnatural amino acids" 256 : 1798-1802, 1992

15 Rozen S, "Primer3 on the WWW for general users and for biologist programmers" 132 : 365-386, 2000

16 Miners JO, "Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug" 57 : 284-289, 1997

17 Zhou S, "Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid" 65 : 1853-1865, 2003

18 Ando Y, "Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis" 60 : 6921-6926, 2000

19 Swen JJ, "Pharmacogenetics: from bench to byte--an update of guidelines" 89 : 662-673, 2011

20 Hishinuma A, "Missense mutation (C1263R) in the thyroglobulin gene causes congenital goiter with mild hypothyroidism by impaired intracellular transport" 45 : 315-327, 1998

21 Lévesque E, "Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene" 7 : 317-325, 1997

22 Zhang JY, "Involvement of human UGT2B7 and 2B15 in rofecoxib metabolism" 31 : 652-658, 2003

23 Kim K, "Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-induced targeting of microRNA-17-92/106b-25clusters" 11 : 1852-1862, 2012

24 Parmar S, "Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer" 13 : R57-, 2011

25 Aono S, "Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II" 197 : 1239-1244, 1993

26 Sugatani J, "Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia" 292 : 492-497, 2002

27 Barrett JC, "Haploview: analysis and visualization of LD and haplotype maps" 21 : 263-265, 2005

28 Jinno H, "Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D" 31 : 108-113, 2003

29 Mackenzie P, "Glucosidation of hyodeoxycholic acid by UDP-glucuronosyltransferase 2B7" 65 : 417-421, 2003

30 Gil J, "Gilbert syndrome: the UGT1A1*28 promoter polymorphism as a biomarker of multifactorial diseases and drug metabolism" 6 : 223-230, 2012

31 van der Logt EM, "Genetic polymorphism in UDP-glucuronosyltransferase 2B7 and colorectal cancer risk" 17 : 323-329, 2009

32 Yuan HY, "FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization" 34 : W635-W641, 2006

33 Chung JY, "Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers" MOSBY 77 (77): 486-494, 2005

34 Liston HL, "Drug glucuronidation in clinical psychopharmacology" 21 : 500-515, 2001

35 Lin R, "Common variants of four bilirubin metabolism genes and their association with serum bilirubin and coronary artery disease in Chinese Han population" 19 : 310-318, 2009

36 Gagné JF, "Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)" 62 : 608-617, 2002

37 Lacko M, "Combined effect of genetic polymorphisms in phase I and II biotransformation enzymes on head and neck cancer risk" 35 : 858-867, 2013

38 Baranano DE, "Biliverdin reductase: a major physiologic cytoprotectant" 99 : 16093-16098, 2002

39 Aono S, "Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert’s syndrome" 345 : 958-959, 1995

40 Lin GF, "An association of UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism with bladder cancer in benzidine-exposed workers in China" 85 : 502-506, 2005

41 Takahashi N, "Amino acid substitutions in genetic variants of human serum albumin and in sequences inferred from molecular cloning" 84 : 4413-4417, 1987

42 Duguay Y, "A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity" 75 : 223-233, 2004

43 Devlin B, "A comparison of linkage disequilibrium measures for fine-scale mapping" 29 : 311-322, 1995